专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

AU2008318778A1 Targeting microRNAs for the treatment of liver cancer 未知
公开(公告)号：AU2008318778A1
公开(公告)日：2009-05-07
申请号：AU2008318778
申请日：2008-10-29
申请人： REGULUS THERAPEUTICS INC , ROSETTA GENOMICS LTD
发明人： ESAU CHRISTINE , CHAJUT AYELET , YERUSHALMI NOGA , BENNETT C FRANK , MARCUSSON ERIC G
IPC分类号： A61K31/7105 , A61P35/00 , C12N15/113

2. 发明专利

AU2008318778B2 Targeting microRNAs for the treatment of liver cancer 未知
公开(公告)号：AU2008318778B2
公开(公告)日：2014-10-02
申请号：AU2008318778
申请日：2008-10-29
申请人： REGULUS THERAPEUTICS INC , ROSETTA GENOMICS LTD
发明人： CHAJUT AYELET , MARCUSSON ERIC G , YERUSHALMI NOGA , ESAU CHRISTINE , BENNETT C FRANK
IPC分类号： A61K31/7105 , A61P35/00 , C12N15/113
摘要： Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.

3. 发明专利

CA2704043A1 TARGETING MICRORNAS FOR THE TREATMENT OF LIVER CANCER 未知
公开(公告)号：CA2704043A1
公开(公告)日：2009-05-07
申请号：CA2704043
申请日：2008-10-29
申请人： ROSETTA GENOMICS LTD , REGULUS THERAPEUTICS INC
发明人： BENNETT C FRANK , CHAJUT AYELET , ESAU CHRISTINE , MARCUSSON ERIC G , YERUSHALMI NOGA
IPC分类号： A61K31/7105 , A61P35/00 , C12N15/113
摘要： Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.

4. 发明专利

CA2704043C TARGETING MICRORNAS FOR THE TREATMENT OF LIVER CANCER 未知
公开(公告)号：CA2704043C
公开(公告)日：2018-09-18
申请号：CA2704043
申请日：2008-10-29
申请人： ROSETTA GENOMICS LTD , REGULUS THERAPEUTICS INC
发明人： BENNETT C FRANK , CHAJUT AYELET , ESAU CHRISTINE , MARCUSSON ERIC G , YERUSHALMI NOGA
IPC分类号： A61K31/7105 , A61P35/00 , C12N15/11 , C12N15/113
摘要： Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.

5. 发明申请

WO2009058907A3 TARGETING MICRORNAS FOR THE TREATMENT OF LIVER CANCER 审中-公开
标题翻译：靶向MICRNANA治疗肝癌
公开(公告)号：WO2009058907A3
公开(公告)日：2009-12-17
申请号：PCT/US2008081645
申请日：2008-10-29
申请人： ISIS PHARMACEUTICALS INC , ROSETTA GENOMICS LTD , BENNETT C FRANK , CHAJUT AYELET , ESAU CHRISTINE , MARCUSSON ERIC G , YERUSHALMI NOGA
发明人： BENNETT C FRANK , CHAJUT AYELET , ESAU CHRISTINE , MARCUSSON ERIC G , YERUSHALMI NOGA
IPC分类号： A61K31/7105 , A61P35/00 , C12N15/113
CPC分类号： C12N15/113 , A61K31/407 , A61K31/44 , A61K31/4745 , A61K31/513 , A61K31/555 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K31/7088 , A61K31/7105 , A61K45/06 , C12N2310/113 , C12N2310/141 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/346 , C12N2310/3525
摘要： Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
摘要翻译：本文提供了用于治疗肝癌的方法。这些方法包括施用包含修饰的寡核苷酸的化合物，其中修饰的寡核苷酸靶向miRNA。本文还提供了用于治疗肝癌的组合物。这样的组合物包括含有修饰的寡核苷酸的化合物，其中修饰的寡核苷酸靶向miRNA。某些miRNA已被鉴定为在肝癌中过表达，例如肝细胞癌，因此被选择用于通过修饰的寡核苷酸进行靶向。此外，某些miRNA已经在暴露于二恶英的肝细胞癌细胞中被鉴定为过表达，并因此被选择用于通过修饰的寡核苷酸进行靶向。已经发现某些这些miRNA的反义抑制抑制细胞增殖并诱导细胞凋亡。

6. 发明专利

AU2011254085B2 Methods for use in modulating miR-122a 未知
公开(公告)号：AU2011254085B2
公开(公告)日：2012-11-01
申请号：AU2011254085
申请日：2011-12-15
申请人： REGULUS THERAPEUTICS INC
发明人： BHANOT SANJAY , ESAU CHRISTINE
IPC分类号： A61K31/711 , C12N15/113
摘要： METHODS FOR USE IN MODULATING MIR-122A Abstract Methods are provided for the treatment of cardiovascular or metabolic diseases characterized by elevated serum total cholesterol, elevated serum LDL-cholesterol, or 5 elevated serum triglycerides, through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Further provided are methods for reducing hepatic steatosis or liver tissue triglyceride accumulation through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Such methods .employ oligomeric compounds which hybridize with or 1o sterically interfere with nucleic acid molecules comprising or encoding miR-122a. Such oligomeric compounds may include one or more modifications thereon, which may improve the activity, stability, or nuclease resistance of the oligomeric compound. These modified oligomeric compounds are used as single compounds or in compositions, including pharmaceutical compositions, to modulate or mimic the targeted nucleic acid is comprising or encoding miR-122a.

7. 发明专利

AU2011254085A1 Methods for use in modulating miR-122a 未知
公开(公告)号：AU2011254085A1
公开(公告)日：2012-01-19
申请号：AU2011254085
申请日：2011-12-15
申请人： REGULUS THERAPEUTICS INC
发明人： BHANOT SANJAY , ESAU CHRISTINE
IPC分类号： A61K31/711 , C12N15/113
摘要： METHODS FOR USE IN MODULATING MIR-122A Abstract Methods are provided for the treatment of cardiovascular or metabolic diseases characterized by elevated serum total cholesterol, elevated serum LDL-cholesterol, or 5 elevated serum triglycerides, through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Further provided are methods for reducing hepatic steatosis or liver tissue triglyceride accumulation through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Such methods .employ oligomeric compounds which hybridize with or 1o sterically interfere with nucleic acid molecules comprising or encoding miR-122a. Such oligomeric compounds may include one or more modifications thereon, which may improve the activity, stability, or nuclease resistance of the oligomeric compound. These modified oligomeric compounds are used as single compounds or in compositions, including pharmaceutical compositions, to modulate or mimic the targeted nucleic acid is comprising or encoding miR-122a.

8. 发明专利

DE602006019455D1 VERFAHREN FÜR MIR-122A-MODULATION 未知
公开(公告)号：DE602006019455D1
公开(公告)日：2011-02-17
申请号：DE602006019455
申请日：2006-08-29
申请人： REGULUS THERAPEUTICS INC
发明人： ESAU CHRISTINE , BHANOT SANJAY
IPC分类号： A61K31/711 , C12N15/113

9. 发明专利

AT494372T 未知
公开(公告)号：AT494372T
公开(公告)日：2011-01-15
申请号：AT06813949
申请日：2006-08-29
申请人： REGULUS THERAPEUTICS INC
发明人： ESAU CHRISTINE , BHANOT SANJAY
IPC分类号： A61K31/711 , C12N15/113
摘要： Methods are provided for the treatment of cardiovascular or metabolic diseases characterized by elevated serum total cholesterol, elevated serum LDL-cholesterol, or elevated serum trigylcerides, through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Further provided are methods for reducing hepatic steatosis or liver tissue triglyceride accumulation through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Such methods employ oligomeric compounds which hybridize with or sterically interfere with nucleic acid molecules comprising or encoding miR-122a. Such oligomeric compounds may include one or more modifications thereon, which may improve the activity, stability, or nuclease resistance of the oligomeric compound. These modified oligomeric compounds are used as single compounds or in compositions, including pharmaceutical compositions, to modulate or mimic the targeted nucleic acid comprising or encoding miR-122a.

10. 发明专利

DK1931780T3 ANTISENSE-FORBINDELSER MED FORØGET ANTI-MICRORNA-AKTIVITET 未知
公开(公告)号：DK1931780T3
公开(公告)日：2016-01-25
申请号：DK06802706
申请日：2006-08-29
申请人： REGULUS THERAPEUTICS INC
发明人： ESAU CHRISTINE , SWAYZE ERIC E
IPC分类号： C12N15/11 , C12N15/113

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式